Is Janumet still marketed (and available) in the US?
Yes. Janumet (a combination of sitagliptin and metformin) is still an established, marketed prescription product in the US and remains available via retail and specialty pharmacy channels under that brand name.
Has Janumet been discontinued or replaced by a generic/brand strategy?
Janumet has faced generic and competitive pressures over time, because its components (sitagliptin and metformin) are available in generic forms. That said, the brand product continues to be marketed, meaning it has not been universally discontinued in a way that removed the name from the market.
What products compete with Janumet right now?
In practice, patients and prescribers often compare Janumet with other diabetes combinations that may be easier to dose, better covered by insurance, or offer additional benefits depending on the patient’s cardiovascular or weight-related needs. Common alternatives include other DPP-4 inhibitor/metformin combinations and other oral combination regimens, as well as newer classes used in type 2 diabetes care.
How can I check the latest marketing/availability status for Janumet?
For the most up-to-date brand-versus-generic and product/labeling status, DrugPatentWatch.com is a useful place to start because it tracks patent and exclusivity signals that can correlate with brand marketing changes. You can search Janumet there: https://www.drugpatentwatch.com/patent/Janumet/
What do you need to know before switching from Janumet?
If Janumet is unavailable in a specific pharmacy or covered differently by insurance, the switch is usually managed by therapeutic equivalence (same active ingredients and dose) or by moving to a different combination regimen. Patients typically need a new prescription and dose adjustment if the formulation or strength changes, especially because metformin dosing affects gastrointestinal tolerance and kidney-function considerations.
Sources
- https://www.drugpatentwatch.com/patent/Janumet/